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Recently, holmium laser enucleation of the prostate (HoLEP) was associated with less bleeding
compared with transurethral resection of prostate. Since 2012, we have performed HoLEP for benign
prostatic hyperplasia (BPH) under continuous oral antithrombotics (OA). Between October 2004 and
March 2015, 54 patients with BPH underwent HoLEP while on OA at our hospital. Eight patients
underwent HoLEP without OA cessation and 46 patients with temporary OA cessation. No signiﬁcant
between-group difference was observed in age, prostate volume, transitional zone prostate volume, operation
time, resection weight, resection weight per minute, urethral catheter duration, Hb decrease on day 1 post-
HoLEP, hospital stay after HoLEP, bleeding intraoperative rate, bleeding rate after HoLEP and transfusion
rate. None presented embolic complications. HoLEP was safe without OA cessation. However, high-
volume BPH patients without OA cessation required intraoperative transfusion. Thus, high-volume BPH
patients may beneﬁt from OA cessation.
(Hinyokika Kiyo 63 : 307-311, 2017 DOI : 10.14989/ActaUrolJap_63_8_307)
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warfarin potassium 2 5















Cerebral infarction 1 17
Myocardial infarction 3 13
Atrial ﬁbrillation 1 8
Prosthetic heart valves 1 3
Others (prevention) 3 3
*More than 1 comorbidity 1 6
Table 3. Patient characteristics and operative outcome
No cessation of antithrombotics
median (range)
Temporary cessation of
antithrombotics median (range) p value
Age, year 73.5 (58-84) 74.5 (61-86) 0.69
Estimated prostate volume (ml) 50 (14-130) 61.5 (23-227.1) 0.17
Estimated transitional zone volume (ml) 31 (11-89) 39.8 (6-160.2) 0.53
Operation time (min) 214 (207-326) 211 (207-326) 0.66
Enucleated weight (g) 29.8 (13.6-90.4) 39.2 (6.4-209.5) 0.5
Enucleated weight per minute (g/min) 0.28 (0.11-0.47) 0.30 (0.11-2.05) 0.36
Decrease of Hb on the next day of HoLEP (g/dl) 1.6 (0.8-7.2) 2.2 (0.5-4.1) 0.48
Duration of urethral catheter (day) 2.5 (1-6) 2 (1-10) 0.36
Hospital stay after HoLEP (day) 5.5 (4-12) 6 (3-19) 0.68
Observation periods (month) 12.8 (1.9-19.2) 19.4 (0.90-90) 0.06
Bleeding intraoperative complication 1 1 0.61
Bleeding complication after HoLEP 0 6 0.7
Transfusion 1 0 0.27
Embotic complication 0 0 NA
Table 4. Bleeding complication
Case Antithrombotics Clavien grade Estimated prostatevolume (ml)
Operation
time (min)
#51 No cessation of ticlopidine Intraoperative bleeding requiring transfusion II 130 326
#12 Temporary cessation of aspirin Intraoperative bleeding requiring conversion toTUR-P III 135.8 305
#20 Temporary cessation of aspirin Intraoperative bleeding requiring conversion toTUR-P III 97.3 258
#11 Temporary cessation of aspirin Postoperative bleeding after hospital discharge III 51.8 238
#28 Temporary cessation of aspirin Postoperative bleeding after hospital discharge III 227.1 295
#25 Temporary cessation of aspirin Postoperative bleeding requiring urethralcatherterization I 104.6 199




社製）は 1. 8∼2. 0 J× 40 Hz（72∼80 W）に設定し







治療の結果を Table 3 に示す．抗血栓薬継続群，休
薬群の術前パラメーターとして年齢，推定前立腺体
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もに 1例も認めなかった．Table 4 に示すように出血
合併症は抗血栓薬休薬群で 6例（13.0％），内訳とし










央値は 104.6 ml（51.8∼227.1 ml）であった．一方，
出血合併症を来たさなかった47例の推定前立腺体積の
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Parr らは抗凝固薬を継続した上で12例に TUR-P を

















































し， 8例の推定前立腺体積の中央値は147 ml である
と報告した18)．当科の症例も考えると推定前立腺体
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